[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Reports Promising Phase 3 Results For Bladder Cancer Treatment Combination",
    "summary": "Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last quarter, Pfizer's stock saw an 11% rise, with these results potentially adding weight to this performance. The company also reached milestones in other research and development areas and maintained strong profitability, exemplified by a net income leap in its Q2 2025 earnings. Despite broader market...",
    "url": "https://finnhub.io/api/news?id=6507ba371cc51c7de41ba0e6e19f0442536b98398c4b536baeaff240ff265aa6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755105552,
      "headline": "Pfizer (PFE) Reports Promising Phase 3 Results For Bladder Cancer Treatment Combination",
      "id": 136339732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last quarter, Pfizer's stock saw an 11% rise, with these results potentially adding weight to this performance. The company also reached milestones in other research and development areas and maintained strong profitability, exemplified by a net income leap in its Q2 2025 earnings. Despite broader market...",
      "url": "https://finnhub.io/api/news?id=6507ba371cc51c7de41ba0e6e19f0442536b98398c4b536baeaff240ff265aa6"
    }
  },
  {
    "ts": null,
    "headline": "PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?",
    "summary": "Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.",
    "url": "https://finnhub.io/api/news?id=b59a7382ab24ae320a1dd9379168cb43dbb8939d95b9279b31facd1b3f8ca225",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755104100,
      "headline": "PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?",
      "id": 136339640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.",
      "url": "https://finnhub.io/api/news?id=b59a7382ab24ae320a1dd9379168cb43dbb8939d95b9279b31facd1b3f8ca225"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=99309668a3862ddb5e79cbda87f1e2d25cc1bf29a55c1abfd4c2fa53df2ab655",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755102960,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 136354467,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=99309668a3862ddb5e79cbda87f1e2d25cc1bf29a55c1abfd4c2fa53df2ab655"
    }
  },
  {
    "ts": null,
    "headline": "Should You Now Consider Selling Your Pfizer (PFE) Shares Before its Too Late?",
    "summary": "Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 […]",
    "url": "https://finnhub.io/api/news?id=fc34bd02b561cc23d347c73a5fc0ed358595397e717c9f6c0f387df98221725b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755100504,
      "headline": "Should You Now Consider Selling Your Pfizer (PFE) Shares Before its Too Late?",
      "id": 136339734,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 […]",
      "url": "https://finnhub.io/api/news?id=fc34bd02b561cc23d347c73a5fc0ed358595397e717c9f6c0f387df98221725b"
    }
  },
  {
    "ts": null,
    "headline": "July Readers Tagged 9 Ideal Dividend Dogs From 17 \"Safer\" Of 40 ReFa/Ro Mentions",
    "summary": "Read about the investment insights from top-yield and high-gain stocks mentioned by our readers.",
    "url": "https://finnhub.io/api/news?id=965deccd71c67a3f71337fd48941065968808710f7e06264f5ee8bf6b4bf13f5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755099653,
      "headline": "July Readers Tagged 9 Ideal Dividend Dogs From 17 \"Safer\" Of 40 ReFa/Ro Mentions",
      "id": 136339130,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292728762/image_1292728762.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Read about the investment insights from top-yield and high-gain stocks mentioned by our readers.",
      "url": "https://finnhub.io/api/news?id=965deccd71c67a3f71337fd48941065968808710f7e06264f5ee8bf6b4bf13f5"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB",
    "summary": "The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enh",
    "url": "https://finnhub.io/api/news?id=016bf5ea612edf87ebda38b794a7bda822ac8a84d056d2e01aedd09cb5f7de92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755091980,
      "headline": "Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB",
      "id": 136328328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enh",
      "url": "https://finnhub.io/api/news?id=016bf5ea612edf87ebda38b794a7bda822ac8a84d056d2e01aedd09cb5f7de92"
    }
  },
  {
    "ts": null,
    "headline": "Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?",
    "summary": "Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.",
    "url": "https://finnhub.io/api/news?id=39c0d26d75f4c4c0cfdc73fdb5edb4a2c3b5734d2b172198bc861833bff60f4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755089520,
      "headline": "Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?",
      "id": 136339641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.",
      "url": "https://finnhub.io/api/news?id=39c0d26d75f4c4c0cfdc73fdb5edb4a2c3b5734d2b172198bc861833bff60f4f"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer",
    "summary": "This big pharma company's juicy dividend is looking even more attractive.",
    "url": "https://finnhub.io/api/news?id=a4203c5863e99190c67e881ce663ad3a8288427cd1e774ec828df14b8dfc7fa7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755075060,
      "headline": "3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer",
      "id": 136328411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This big pharma company's juicy dividend is looking even more attractive.",
      "url": "https://finnhub.io/api/news?id=a4203c5863e99190c67e881ce663ad3a8288427cd1e774ec828df14b8dfc7fa7"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys",
    "summary": "See here for more on July's investment insights: record-breaking dividends, high-yield BDCs, and strategies for steady income growth.",
    "url": "https://finnhub.io/api/news?id=642c79a5d7ace207c9d722f9b6e969419b05a47cf1edf5c3505e32f7b283a55b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755072900,
      "headline": "My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys",
      "id": 136327951,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "See here for more on July's investment insights: record-breaking dividends, high-yield BDCs, and strategies for steady income growth.",
      "url": "https://finnhub.io/api/news?id=642c79a5d7ace207c9d722f9b6e969419b05a47cf1edf5c3505e32f7b283a55b"
    }
  },
  {
    "ts": null,
    "headline": "PFE Q2 Deep Dive: Margin Expansion and R&D Pipeline Fuel Outlook Amid Policy Uncertainty",
    "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $14.65 billion. The company expects the full year’s revenue to be around $62.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.78 per share was 35.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=403228885a2adfc53f47e1733d9a98a0b6bd7c6bf95064faddd366ca4f5e8800",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755059060,
      "headline": "PFE Q2 Deep Dive: Margin Expansion and R&D Pipeline Fuel Outlook Amid Policy Uncertainty",
      "id": 136328412,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $14.65 billion. The company expects the full year’s revenue to be around $62.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.78 per share was 35.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=403228885a2adfc53f47e1733d9a98a0b6bd7c6bf95064faddd366ca4f5e8800"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Pfizer’s Q2 Earnings Call",
    "summary": "Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this performance to a robust showing across its commercial portfolio, especially in oncology, vaccines, and rare disease products. CEO Albert Bourla highlighted that disciplined cost control and productivity enhancements—including expanded use of automation and AI—contributed to improved operating margins. The compa",
    "url": "https://finnhub.io/api/news?id=22cbcd1b1f1fdda2a94fa106e83165a79c58676fd1c3e18da9fbef08a7120f22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755058921,
      "headline": "The Top 5 Analyst Questions From Pfizer’s Q2 Earnings Call",
      "id": 136328413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this performance to a robust showing across its commercial portfolio, especially in oncology, vaccines, and rare disease products. CEO Albert Bourla highlighted that disciplined cost control and productivity enhancements—including expanded use of automation and AI—contributed to improved operating margins. The compa",
      "url": "https://finnhub.io/api/news?id=22cbcd1b1f1fdda2a94fa106e83165a79c58676fd1c3e18da9fbef08a7120f22"
    }
  }
]